GlassScriptPhysician profile
Maryam Ardalan
NPI 1396936217
$2,631.03
in general payments reported to CMS, 2019-2025
24 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Obstetrics provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,308 · 2020: $251 · 2021: $152 · 2022: $146 · 2023: $174 · 2024: $265 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $773.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $1,162.65 | 2019 | |
| Abbvie INC. | $364.32 | 2019-2023 | Liletta |
| Hologic Sales and Service, LLC | $135.19 | 2020-2025 | Aptima, Thinprep 2000 Processor |
| Exeltis, USA INC. | $123.71 | 2023-2025 | Slynd |
| Galderma Laboratories, L.P. | $102.73 | 2024 | |
| Myovant Sciences INC. | $84.85 | 2022 | |
| Organon LLC | $73.61 | 2022-2025 | Nexplanon, Jada System |
| Therapeuticsmd, INC. | $69.51 | 2019-2021 | |
| Shield Therapeutics INC | $65.62 | 2023-2025 | Accrufer |
| Coopersurgical, INC. | $56.02 | 2020-2023 | Paragard T 380a |
| Sumitomo Pharma America, INC. | $51.95 | 2024-2025 | Myfembree |
| Astellas Pharma US INC | $37.72 | 2024-2025 | Veozah |
| Pfizer INC. | $35.28 | 2022-2023 | |
| Sage Therapeutics, LLC | $33.18 | 2024 | |
| Roche Diagnostics Corporation | $30.00 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Applied Medical Resources Corporation | $28.19 | 2025 | Gelpoint V-Path |
| Meditrina | $26.03 | 2025 | |
| Amag Pharmaceuticals, INC. | $24.18 | 2020 | |
| Mayne Pharma Commercial LLC | $23.48 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.47 | 2025 | |
| Evofem Biosciences, INC. | $23.19 | 2023-2025 | Phexxi, Solosec, Phexx |
| Medtronic, INC. | $22.69 | 2024 | Abre |
| Smith+Nephew, INC. | $17.67 | 2024 | Pico |
| Allergan, INC. | $15.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maryam Ardalan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.